The DuoResp Spiromax inhaler from Teva Pharmaceutical Industries received an award at the 2015 Medical Design Excellence Awards.
Teva Pharmaceutical Industries Ltd today announced that its DuoResp Spiromax inhaler has won silver at the 2015 Medical Design Excellence Awards (MDEA). The awards recognize significant advances in medical product design that improve the quality of healthcare delivery. DuoResp Spiromax (budesonide/formoterol fumarate dihydrate) is a new multi-dose dry-powder inhaler for the management of asthma and COPD.
“Innovative, patient-focused design is extremely important at a time when real-world behaviors and outcomes are what count,” said Rob Koremans, MD, President and CEO, Teva Global Specialty Medicines. “We are incredibly proud to be leading the way in providing people with asthma and COPD with inhalers that recognize and support their needs and long-term health, and are delighted with this prestigious acknowledgment for DuoResp Spiromax.”
